Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

Innovation

Have you ever wondered why cell therapies remain so expensive and hard to bring to patients worldwide, despite incredible scientific advances?

Dr. David Brühlmann

CMC Strategist

CMC and Bioprocess Blog

Execution-focused articles on CMC strategy, bioprocess scale-up, tech transfer, CDMO selection, and GMP readiness for process development scientists and manufacturing leaders scaling biologics into regulatory-ready therapies.

Bioprocessing

For many biotech innovators, high throughput screening platforms promise faster discoveries and streamlined workflows.

Bioprocessing

Why do so many promising biotech ideas stall—long before they reach the clinic or marketplace?

Innovation

Imagine medicines grown like crops, ready for harvest in days, not months.

Innovation

But what if you could grow life-saving antibodies in a greenhouse instead?

Biotech Success

Complex automation often arrives wrapped in hype, but the reality is more nuanced.

Biotech Success

Are you struggling with automation projects that spiral into unnecessary complexity or fail to solve the real problem in bioprocessing?

Bioprocessing

What’s the real difference between a shake flask, a microtiter plate, and a full-scale bioreactor—and why do so many experiments go sideways, even when the SOP looks perfect?

Bioprocessing

In bioprocess development, orbital-shaken bioreactors—shake flasks, spin tubes, and microtiter plates—are the unsung backbone powering industry decisions about production strains and media.

Bioprocessing

What if the difference between a seamless tech transfer and a costly setback isn’t your process, but how you orchestrate the people and details behind the scenes?

Bioprocessing

Tech transfer in biotech can feel like a high-stakes gamble, balancing regulatory shifts, incomplete data, and mounting stakeholder pressure—all with timelines breathing down your neck.

Bioprocessing

For many biotech innovators, high throughput screening platforms promise faster discoveries and streamlined workflows.

Bioprocessing

Why do so many promising biotech ideas stall—long before they reach the clinic or marketplace?

Data & Analytics

What does it take to crack the code of protein production—and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers?

Data & Analytics

Somewhere in your lab, a hard drive is quietly storing omics data that hasn’t seen the light of day in years—genome sequences, metabolomics runs, scribbled notes in aging ELNs.

Data & Analytics

Leveraging digital models and AI-powered tools can make all the difference for both R&D and manufacturing, but finding the right starting point—and justifying the investment—can feel overwhelming.

Data & Analytics

Is your bioprocess development stacked with siloed data, endless spreadsheets, and a constant battle to identify where to start your digital transformation?

Data & Analytics

What separates labs with truly connected, AI-ready data from those drowning in digital chaos?

Data & Analytics

What if the real bottleneck in biotech labs isn’t equipment, talent, or even funding—but a silent issue lurking in plain sight: fragmented data?

Biotech Success

How do you know when your biotech startup is ready to sell—before the product is “perfect”?

Biotech Success

Most bioprocess innovation is dismissed as a “fool’s game”—until the skeptics are proven wrong.

Biotech Success

What happens when the solution to America’s insulin crisis isn’t a new molecule or fancy delivery device—but a new way of thinking about biotech itself?

Biotech Success

What if affordable insulin isn’t a scientific hurdle—but a financial and distribution puzzle no one’s been motivated to solve?

Biotech Success

Securing capital for biotech innovation has never been more challenging—or more crucial.

Biotech Success

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Innovation

For decades, contract development and manufacturing organizations (CDMOs) have grown by building bigger stainless-steel facilities and squeezing ever-tighter margins.

Innovation

What if continuous microbial manufacturing wasn’t a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?

Innovation

Imagine medicines grown like crops, ready for harvest in days, not months.

Innovation

But what if you could grow life-saving antibodies in a greenhouse instead?

Innovation

If biotech had a “cheat code” for sustainable manufacturing, what would it look like?

Innovation

What if the ocean’s tiniest inhabitants held the secret to decarbonizing the entire chemicals industry?

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.

No spam. Unsubscribe anytime.

Enjoying what you're reading? Get the next deep-dive and digest in your inbox.

The Bioprocess Brief — biweekly digests, deep-dives, and field notes on biologics, cell and gene therapies, and AI-driven bioprocessing, written by a CMC practitioner.


No spam. Unsubscribe anytime.